Loading...

Cellectis S.A.

ALCLS.PA•EURONEXT
Healthcare
Biotechnology
€1.36
€0.03(2.10%)

Cellectis S.A. (ALCLS.PA) Stock Overview

Explore Cellectis S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.5/100

Key Financials

Market Cap97.8M
P/E Ratio-2.62
EPS (TTM)$-0.57
ROE-0.46%
Fundamental Analysis

AI Price Forecasts

1 Week$1.34
1 Month$0.63
3 Months$1.89
1 Year Target$0.74

ALCLS.PA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Cellectis S.A. (ALCLS.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.45, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.74.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.62 and a market capitalization of 97.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

53.45RSI (14)
0.01MACD
28.19ADX
Revenue Growth
5397.48%
↑ 5397.48%
Profit Growth
€-0.60
↑ 63.62%
EPS Growth
€-0.60
↑ 80.29%
Operating Margin
-110.93%
↑ 38.79%
ROE
-46.10%
↑ 63.62%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ALCLS.PAAnalyst Recommendations details for ALCLS.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

CEO

Andre Choulika

Employees

216

Headquarters

8, rue de la Croix Jarry, Paris

Founded

2007

Frequently Asked Questions

;